| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/31/2005 | US20050070555 Aroyl pyridinones |
| 03/31/2005 | US20050070553 Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 03/31/2005 | US20050070541 Enzyme inhibitors of cGMP-metabolizing phosphodiesterases, for TREATMENT OF CARDIOVASCULAR DIORDERS, CEREBROVASCULAR DISORDERS, UROGENITAL DISORDERS AND ERECTILE DYSFUNCTION; chemical synthesis |
| 03/31/2005 | US20050070535 Antidiabetic agents; obesity; controlling appetite |
| 03/31/2005 | US20050070531 Using such as 2-[2-(3-Amino-piperidin-1-yl)4-oxo-4H-quinazolin-3-ylmethyl]-benzonitrile to treat cancer and/or autoimmune disorder |
| 03/31/2005 | US20050070530 Dipeptidyl peptidase inhibitors |
| 03/31/2005 | US20050070521 Alkyl ether derivatives or salts thereof |
| 03/31/2005 | US20050070514 Administering phosphodiesterase 4 inhibitor in combination with beta agonist and an anti-inflammatory steroid |
| 03/31/2005 | US20050070510 Tetracycline compound of given formula, an antifungal agent such as amphotericin B and a carrier; treating fungal infections |
| 03/31/2005 | US20050070505 Phosphinic pseudo-peptide derivatives for the selective inhibition of the active c-terminal site of angiotensin converting enzyme (I) (ace) |
| 03/31/2005 | US20050070491 Immunostimulatory nucleic acid molecules |
| 03/31/2005 | US20050070485 Phenylalanine derivatives |
| 03/31/2005 | US20050070482 Peptides substituted with a functional group that reacts with an active site residue of the targeted protease, e.g., Cyclohexylglycine BoroAla, and compounds that can hydrolyzed to produce them; improved specificity for regulating glucose metabolism |
| 03/31/2005 | US20050070481 By adding an antioxidant and/or a chelating agent in the same aqueous solution; reduced coenzyme Q10, vitamin C and ethylenediaminetetracetic acid for example |
| 03/31/2005 | US20050070480 Peptide arginals and methods for treating disseminated intravascular coagulation |
| 03/31/2005 | US20050070465 Polypeptide, the conjugate thereof with doxorubicine and a pharmaceutical composition based thereon |
| 03/31/2005 | US20050070459 treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor |
| 03/31/2005 | US20050070015 Methods of controlling proliferation of cancer cells and cell death |
| 03/31/2005 | US20050069983 Nucleotide sequences coding membrane protein for use in identifying modulator for prevention and treatment of herpes viral infection, cell proliferative and autoimmune disorders |
| 03/31/2005 | US20050069980 Transport protein for use as tool in altering in vivo pharmacokinetics of a pharmaceutical, toxic substance or xenobiotics by modulating an ability to transport acidic amino acids; antitumor agents |
| 03/31/2005 | US20050069943 101 human secreted proteins |
| 03/31/2005 | US20050069919 Novel human secreted proteins and polynucleotides encoding the same |
| 03/31/2005 | US20050069888 Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof |
| 03/31/2005 | US20050069877 Protein modification and maintenance polypeptides (PMOD) for use as diagnostic and therapeutic tools in treatment of prevention of gastrointestinal, cardiovascular, autoimmune/inflammatory, cell proliferative, developmental, epithelial, neurological, and reproductive disorders |
| 03/31/2005 | US20050069866 Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| 03/31/2005 | US20050069598 Antidiabetic agents; moderate glucagon-like peptide; phosphoenolpyruvate carboxykinase inhbitors; weight control |
| 03/31/2005 | US20050069580 Compositions containing both sedative and non-sedative antihistamines and sleep aids |
| 03/31/2005 | US20050069577 Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies |
| 03/31/2005 | US20050069535 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides |
| 03/31/2005 | US20050069492 As neuroprotective agents in the therapy of neuronal disorders of the central and peripheral nervous systems |
| 03/31/2005 | CA2551037A1 Novel piperidine derivative |
| 03/31/2005 | CA2539554A1 Phenylacetic acid derivative, process for producing the same, and use |
| 03/31/2005 | CA2539320A1 Use of chk1 inhibitors to control cell proliferation |
| 03/31/2005 | CA2539165A1 Cinnamoyl compound and use of the same |
| 03/31/2005 | CA2539162A1 Cinnamoyl derivatives and use thereof |
| 03/31/2005 | CA2538960A1 Cinnamoyl compound and use of the same |
| 03/31/2005 | CA2538760A1 Human .beta.-defensin secretion promoter |
| 03/31/2005 | CA2538590A1 Novel gamma secretase inhibitors |
| 03/31/2005 | CA2538366A1 Concurrent drugs |
| 03/31/2005 | CA2538284A1 Modulators of p-selectin glycoprotein ligand 1 |
| 03/30/2005 | EP1519192A2 HIV Protease inhibitor conjugates and antibodies useful in ummunoassay |
| 03/30/2005 | EP1518855A1 Diaminopyrimidinecarboxa mide derivative |
| 03/30/2005 | EP1518854A1 Substituted 06- benzylguanines and 7- or 9- substituted 8-aza-06-benzylguanines |
| 03/30/2005 | EP1518562A2 Dopamine transporter imaging agents |
| 03/30/2005 | EP1518561A2 Dopamine transporter imaging agents |
| 03/30/2005 | EP1518557A1 Anti-hiv agent |
| 03/30/2005 | EP1517989A2 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
| 03/30/2005 | EP1517924A1 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained |
| 03/30/2005 | EP1517909A2 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
| 03/30/2005 | EP1517907A2 Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity |
| 03/30/2005 | EP1517905A1 Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases |
| 03/30/2005 | EP1517899A1 Broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors |
| 03/30/2005 | EP1517896A2 Phenyl- and pyridyl-diazaheterocycles having a tnf-modulating activity |
| 03/30/2005 | EP1517889A2 Nitrooxyderivatives of cyclooxygenase-2 inhibitors |
| 03/30/2005 | EP1517882A1 Amide linker peroxisome proliferator activated receptor modulators |
| 03/30/2005 | EP1517708A1 Combination treatment for depression and anxiety by nk1 and nk3 antagonists |
| 03/30/2005 | EP1517707A1 Treatment for depression and anxiety with the combination of a pde iv inhibitor and an antidepressant or an anxiolytic agent |
| 03/30/2005 | EP1517705A1 Dichloroacetate in combination with cardioprotective or hemodynamic drugs |
| 03/30/2005 | EP1517704A1 Use of antibodies against flt-1 for the treatment of osteoporosis |
| 03/30/2005 | EP1517703A1 Placental growth factor as a target for the treatment of osteoporosis |
| 03/30/2005 | EP1517695A2 Osteopontin, oligodendrocytes and myelination |
| 03/30/2005 | EP1517685A1 2-(phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses |
| 03/30/2005 | EP1517682A1 Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant |
| 03/30/2005 | EP1517679A1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
| 03/30/2005 | EP1517606A2 Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer |
| 03/30/2005 | EP1450770B1 Pharmaceutical composition comprising a 5ht1 receptor agonist |
| 03/30/2005 | EP1438289B1 Indole derivatives as cox ii inhibitors |
| 03/30/2005 | EP1429648A4 METHODS FOR SCREENING FOR SUBSTANCES WHICH INHIBIT FP PROSTANOID RECEPTOR INTERACTION WITH A COMPOUND HAVING PGF 2$g(a)alpha?ACTIVITY AND METHODS OF TREATING CANCER |
| 03/30/2005 | EP1390037A4 Methods for treating delirium using glucocorticoid receptor-specific antagonists |
| 03/30/2005 | EP1360184B1 Piperidine derivatives as neurokinin 1 antagonists |
| 03/30/2005 | EP1322350B1 E-ptfe foil impregnated with an encapsulated bioactive substance |
| 03/30/2005 | EP1307182B1 Pharmaceutical composition for transdermal delivery of befloxatone |
| 03/30/2005 | EP1250132B1 Ibuprofen containing active agent preparation |
| 03/30/2005 | EP1246692B1 Templating of uncharged solid particles by polymer multilayers |
| 03/30/2005 | EP1237898B1 N?6 heterocyclic 8-modified adenosine derivatives |
| 03/30/2005 | EP1224163B1 Use of carbonylamino derivatives against cns disorders |
| 03/30/2005 | EP1203088B1 Conditionally controlled, attenuated hiv vaccine |
| 03/30/2005 | EP1194429B1 Potassium channel openers |
| 03/30/2005 | EP1192127B1 Substituted benzamide inhibitors of rhinovirus 3c protease |
| 03/30/2005 | EP1185294B1 Peptides for the treatment of impaired interpersonal and behavioral disorders |
| 03/30/2005 | EP1181035B1 Substantially oil-free cyclosporin compositions |
| 03/30/2005 | EP1124570A4 Novel neuropilin/growth factor binding and uses thereof |
| 03/30/2005 | EP1105378B1 Quinazoline derivatives |
| 03/30/2005 | EP1091942B1 Potassium channel blocking agents |
| 03/30/2005 | EP1087765B1 Use of optically pure (-) norcisapride in the treatment of irritable bowel syndrome |
| 03/30/2005 | EP1076561B1 Combination therapy for the treatment of tumors |
| 03/30/2005 | EP1075467B1 Pyrazole derivatives as p-38 map kinase inhibitors |
| 03/30/2005 | EP1001978B1 Angiotensin derivatives |
| 03/30/2005 | EP0980369B1 Sulfonamides for treatment of endothelin-mediated disorders |
| 03/30/2005 | EP0928290B1 Oligoribonucleotides and ribonucleases for cleaving rna |
| 03/30/2005 | EP0877740B1 Thiol derivatives with metallopeptidase inhibitory activity |
| 03/30/2005 | EP0791056B1 Lipid-cleavage enzyme complex |
| 03/30/2005 | EP0758890B1 Use of no scavengers, inhibitors or antagonists in the treatment of migraine |
| 03/30/2005 | CN1602427A Inhibition of tristetraproline for protection of the heart from cardiac injuries |
| 03/30/2005 | CN1602425A Therapeutic and diagnostic uses of antibody specificity profiles |
| 03/30/2005 | CN1602360A Methods of increasing endogenous erythropoietin (EPO) |
| 03/30/2005 | CN1602358A Recombinant fusion proteins and the trimers thereof |
| 03/30/2005 | CN1602317A Angiopoietin-2 specific binding agents |
| 03/30/2005 | CN1602315A Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| 03/30/2005 | CN1602311A Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible NO-synthase |